Hun Ju Lee, MD, discusses dosing of the combination of the investigational ROR1 inhibitor cirmtuzumab and ibrutinib in mantle cell lymphoma and chronic lymphocytic leukemia.
Hun Ju Lee, MD, an associate professor of medicine, Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, discusses dosing of the combination of the investigational ROR1 inhibitor cirmtuzumab and ibrutinib (Imbruvica) in mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL).
At the 2020 ASCO Virtual Scientific Program, findings from a phase 1b/2 trial showed that a 600 mg flat dose of cirmtuzumab plus 420 mg/day of ibrutinib in CLL and 560 mg/day in MCL was selected for part 2 of the expansion cohort.
The combination was well tolerated, says Lee. Grade 1/2 adverse effects consisted mainly of diarrhea, confusion, and fatigue among patients with MCL or CLL.